Niosomal Fast-Dissolving Oral Films: Emerging Platforms for Enhanced Antidiabetic Therapy

Due to the chronic nature of the condition and the drawbacks of traditional oral antidiabetic medication delivery methods, such as poor bioavailability, a delayed beginning of action, and problems with patient compliance, managing diabetes mellitus is a global concern. Novel medication delivery methods that improve patient comfort and therapeutic efficacy have been presented by recent developments in pharmaceutical technology. Niosomal fast-dissolving oral films (FDOFs), which combine the advantages of niosomes with fast-dissolving film technology, have attracted a lot of interest among these innovations. Both hydrophilic and lipophilic medications can be encapsulated in niosomes, which are non-ionic surfactant-based vesicles that increase stability, release control, and permeability. They provide quick disintegration in the oral cavity when combined with fast-dissolving films, avoiding first-pass metabolism and enabling direct absorption through the buccal mucosa. This results in better glycaemic management, increased bioavailability, and a faster therapeutic onset. Niosomal FDOF formulation necessitates the careful selection of suitable polymers, surfactants, and plasticisers, followed by characterisation according to factors such in vitro drug release, folding endurance, surface pH, and disintegration time. Additionally, these systems have demonstrated encouraging preclinical outcomes when antidiabetic drugs like metformin, glibenclamide, and pioglitazone are added. However, issues including scalability, long-term storage stability, and vesicle stability within the film matrix still need to be looked at. In conclusion, Niosomal fast-dissolving oral films represent a possible breakthrough in contemporary diabetes therapy by providing a patient-friendly, non-invasive, and successful method for boosting the therapeutic efficacy of antidiabetic medications.